Biogen’s Alzheimer’s drug is unlikely to win E.U. approval.
The drug maker Biogen said on Wednesday that a panel of drug reviewers in the European Union had indicated that its new Alzheimer’s drug was unlikely to be approved there, the latest setback for a medication that has been mired in controversy since it was approved in the United States in June. Biogen said a…